Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1

Figure 4

ACT1 cooperates with tamoxifen to promote cytotoxicity in ER+ MCF7 cells. MCF7 cells were treated with vehicle, R-pep (100 μM), or ACT1 (100 μM) in the presence of drug vehicle (DMSO) or tamoxifen citrate (10 μM) for 48 hours and assessed for (A) crystal violet staining density and quantitation by OD540. (B) R-pep and ACT1 treated cells were also assessed by cell counting after co-treatment with drug vehicle (DMSO) or tamoxifen citrate (10 μM) for 48 hours. Student’s T-test was used to assess statistical significance as indicated. ± SEM; n = 3 (A) n = 6 (B).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us